{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:16:09Z","timestamp":1788621369691,"version":"build-2803163510"},"reference-count":32,"publisher":"Japan Society for Clinical Immunology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2177\/jsci.40.83","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T22:14:59Z","timestamp":1497219299000},"page":"83-89","source":"Crossref","is-referenced-by-count":41,"title":["Immune-related adverse events by immune checkpoint inhibitors"],"prefix":"10.2177","volume":"40","author":[{"given":"Takafumi","family":"KADONO","sequence":"first","affiliation":[{"name":"Department of Dermatology, St. Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Michot, J.M., et a1.: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>Eur J Cancer<\/i>. <b>54<\/b>: 139-148, 2016."},{"key":"2","unstructured":"2) Larkin, J., et al.: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>N Engl J Med<\/i>. <b>373<\/b>: 23-34, 2015."},{"key":"3","unstructured":"3) Postow, M.A., et al.: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. <i>N Engl J Med<\/i>. <b>372<\/b>: 2006-2017, 2015."},{"key":"4","unstructured":"4) Horvat, T.Z., et al.: Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. <i>J Clin Oncol<\/i>. <b>33<\/b>: 3193-3198, 2015."},{"key":"5","unstructured":"5) Weber, J.S., et al.: Management of immune-related adverse events and kinetics of response with ipilimumab. <i>J Clin Oncol<\/i>. <b>30<\/b>: 2691-2697, 2012."},{"key":"6","unstructured":"6) Borghaei, H., et al.: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>N Engl J Med<\/i>. <b>373<\/b>: 1627-1639, 2015."},{"key":"7","unstructured":"7) Motzer, R.J., et al.: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>N Engl J Med<\/i>. <b>373<\/b>: 1803-1813, 2015."},{"key":"8","unstructured":"8) Klarquist, J., et al.: Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin. <i>Pigment Cell Melanoma Res<\/i>. <b>29<\/b>: 379-384, 2016."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9) Nakamura, Y., et al.: Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. <i>J Dermatol<\/i>. 2016 Aug 11. doi:10.1111\/1346-8138.13520.","DOI":"10.1111\/1346-8138.13520"},{"key":"10","unstructured":"10) Freeman-Keller, M., et al.: Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. <i>Clin Cancer Res<\/i>. <b>22<\/b>: 886-894, 2016."},{"key":"11","unstructured":"11) Motzer, R.J., et al.: Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>J Clin Oncol<\/i>. <b>33<\/b>: 1430-1437, 2015."},{"key":"12","unstructured":"12) Rizvi, N.A., et al.: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncol<\/i>. <b>16<\/b>: 257-265, 2015."},{"key":"13","unstructured":"13) Klein, O., et al.: Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. <i>Clin Cancer Res<\/i>. <b>15<\/b>: 2507-2513, 2009."},{"key":"14","unstructured":"14) Robert, C., et al.: Nivolumab in previously untreated melanoma without BRAF mutation. <i>N Engl J Med<\/i>. <b>372<\/b>: 320-330, 2015."},{"key":"15","unstructured":"15) Ribas, A., et al.: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncol<\/i>. <b>16<\/b>: 908-918, 2015."},{"key":"16","unstructured":"16) Weber, J.S., et al.: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncol<\/i>. <b>16<\/b>: 375-384, 2015."},{"key":"17","unstructured":"17) \u5c0f\u91ce\u85ac\u54c1\u5de5\u696d\u682a\u5f0f\u4f1a\u793e\uff0e\u30aa\u30d7\u30b8\u30fc\u30dc\u00ae\u5b89\u5168\u6027\u30fb\u9069\u6b63\u4f7f\u7528\u60c5\u5831\uff0ehttps:\/\/www.opdivo.jp\/contents\/report\/"},{"key":"18","unstructured":"18) Nishino, M., et al.: Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. <i>Cancer Immunol Res<\/i>. <b>4<\/b>: 289-293, 2016."},{"key":"19","unstructured":"19) Arriola, E., et al.: Infliximab for IPILIMUMAB-related colitis. <i>Clin Cancer Res<\/i>. <b>21<\/b>: 5642-5643, 2015."},{"key":"20","unstructured":"20) Robert, C., et al.: Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>N Engl J Med<\/i>. <b>372<\/b>: 2521-2532, 2015."},{"key":"21","unstructured":"21) Kim, K.W., et al.: Ipilimumab-associated colitis: CT findings. <i>AJR Am J Roentgenol<\/i>. <b>200<\/b>: W468-474, 2013."},{"key":"22","unstructured":"22) Spain, L., et al.: Management of toxicities of immune checkpoint inhibitors. <i>Cancer Treat Rev<\/i>. <b>44<\/b>: 51-60, 2016."},{"key":"23","unstructured":"23) Yanai, S., et al.: Nivolumab-Induced Colitis Treated by Infliximab. <i>Clin Gastroenterol Hepatol<\/i>. pii: S1542-3565(16)30675-30659, 2016."},{"key":"24","unstructured":"24) Pag\u00e8s, C., et al.: Ipilimumab-induced acute severe colitis treated by infliximab. <i>Melanoma Res<\/i>. <b>23<\/b>: 227-230, 2013."},{"key":"25","unstructured":"25) Merrill, S.P., et al.: Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. <i>Ann Pharmacother<\/i>. <b>48<\/b>: 806-810, 2014."},{"key":"26","unstructured":"26) Minor, D.R., et al.: Infliximab in the treatment of anti-CTLA4 antibody. <i>Cancer Biother Radiopharm<\/i>. <b>24<\/b>: 321-325, 2009."},{"key":"27","doi-asserted-by":"publisher","unstructured":"27) Tanaka, A., et al.: Critical renal adverse event induced by nivolumab therapy in a stage IV melanoma patient. <i>J Dermatol<\/i>. 2016 Jul 27. doi:10.1111\/1346-8138.13538.","DOI":"10.1111\/1346-8138.13538"},{"key":"28","unstructured":"28) Ryder, M., et al.: Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. <i>Endocr Relat Cancer<\/i>. <b>21<\/b>: 371-381, 2014."},{"key":"29","unstructured":"29) Kimura, T., et al.: Myasthenic crisis and polymyositis induced by one dose of nivolumab. <i>Cancer Sci<\/i>. <b>107<\/b>: 1055-1058, 2016."},{"key":"30","unstructured":"30) de Velasco, G., et al.: Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment. <i>Arthritis Rheumatol<\/i>. <b>68<\/b>: 556-557, 2016."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Arai, T., et al.: Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. <i>J Dermatol<\/i>. 2016 Sep 21. doi:10.1111\/1346-8138.13612.","DOI":"10.1111\/1346-8138.13612"},{"key":"32","unstructured":"32) Karlin, J., et al.: Bilateral Anterior Uveitis Associated with Nivolumab Therapy. <i>Ocul Immunol Inflamm<\/i>. 2016 Sep 6: 1-3."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306b\u3088\u308b\u514d\u75ab\u95a2\u9023\u526f\u4f5c\u7528\u306e\u5b9f\u969b"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/40\/2\/40_83\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T22:17:32Z","timestamp":1569449852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/40\/2\/40_83\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.40.83","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}